83-5963-89　PDL1, Atezolizumab Biosimilar 1mg　591677

特徴

• Atezolizumab biosimilar is an Fc-engineered, humanized, monoclonal antibody that binds to PD-L1 and blocks interactions with the PD-1 and B7.1 receptors.
• Atezolizumab biosimilar is a non-glycosylated IgG1 kappa immunoglobulin that has a calculated molecular mass of 145kD.
• Atezolizumab has been extensively studied in cancer research for its ability to inhibit one of the main immune checkpoint pathways and enhance T-cell-mediated immune response against tumor cells.
• Atezolizumab was first approved by the FDA in May 2016 for the treatment of bladder cancer and is now used to treat advanced types of TNBC (triple-negative breast cancer), NSCLC (non-small cell lung cancer), small cell lung cancer and urothelial carcinoma.
• Based on its potential clinical benefit, it is also under investigation for other types of advanced and metastatic cancers.
• Here are some examples of atezolizumab’s latest research.
• Narayan et al.
• (2020) published in Clinical Cancer Research a summary of IMpassion130, the randomized study that allowed FDA approval for the use of atezolizumab in combination with paclitaxel-protein bound for the treatment of patients with advanced or metastatic TNBC.
• The authors not only summarized the data but also analyzed the benefit of this combination treatment after 13 months.
• The promising initial results were confirmed when they observed an improved estimated progression-free survival for patients treated with atezolizumab (7.4 months) compared to patients in the placebo group (4.8 months).
• In a study by Kurzrock et al.
• (2020), the objective response rate of atezolizumab was measured for SGC (salivary gland carcinoma) patients.
• SGCs do not usually respond well to common chemotherapy and because of the rarity of the disease, only a few studies focused on finding effective treatments.
• Here, using data from the multi-center study MyPathway, the authors observed promising partial response and prolonged stable disease in a patient with high tumor mutational burden treated with atezolizumab alone.
• Okauchi et al.
• (2020) described the benefit of combination therapy with common chemotherapeutic agents and an immune checkpoint inhibitor for a patient with double primary cancers (metastatic lung adenocarcinoma and locally advanced epipharyngeal carcinoma).
• The authors observed not only the regression of both cancers but also no signs of tumor progression after 7 months.
• This so far, the only study providing proof of principle that the combination of chemotherapy and immune checkpoint inhibitors may be effective to treat double primary cancers.
• Hopkins et al.
• (2020) designed a study to create a prognostic tool of survival for patients with advanced lung cancer treated with immune checkpoint inhibitors.
• Using clinicopathological and development data from the randomized trials OAK and POPLAR, they analyzed overall survival and progression-free survival as primary and secondary outcomes respectively.
• According to their study, they successfully developed a prognostic tool to identify patients who could benefit from atezolizumab therapy.
• At the same time, Zhao et al.
• (2020) performed a systematic search for randomized controlled trials of the most common checkpoint inhibitors to measure fatal adverse events associated with their use in patients with various cancers.
• Interestingly, they found that so far, monotherapy with PD-1/PD-L1 inhibitors is positively associated with reduced risk of mortality in patients with solid tumors compared to traditional therapy.
• Applications:Suitable for use in Functional Assays.
• Other applications not tested.
• Recommended Dilution:Optimal dilutions to be determined by the researcher.
• Storage and Stability:May be stored at 4℃ for short-term only.
• Aliquot to avoid repeated freezing and thawing.
• Store at -20℃.
• Aliquots are stable for 12 months after receipt.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.